Biosimilars in the EU: New IMS Report Shows Savings Through Competition
By Zachary Brennan -
Published 09 May 2017
A new report released Tuesday, prepared by QuintilesIMS at the request of the European Commission, found EU countries are saving lots of money from biosimilars even if market share is low.
Categories: News, Europe, EC, EMA, Biologics and biotechnology, Government affairs, Regulatory intelligence, Regulatory strategy, Reimbursement
Tags: biosimilars, biologic competition, anti-TNF, HGH